Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


Shaji K. Kumar, MD, on How CAR T-Cell Therapies Are Changing the Therapeutic Landscape in Multiple Myeloma

Posted: Wednesday, May 10, 2023

Shaji K. Kumar, MD, of the Mayo Clinic, Rochester, Minnesota, discusses how two chimeric antigen receptor (CAR) T-cell therapies—idecabtagene vicleucel and ciltacabtagene autoleucel—are changing the therapeutic landscape in the clinic for patients with multiple myeloma. He briefly explores both the benefits and adverse events associated with these immunotherapies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.